Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25075210 | 0.93 | GNAO1 (0.37) | GNAO1KCNH2GNAI3GNAI1 | |
| SCHEMBL25075207 | 0.85 | GNAI3 (0.38) | PRMT6CARM1PRMT1PRMT8GNAO1 | |
| SCHEMBL26742235 | 0.84 | GNAO1 (0.38) | GNAO1GNAI3GNAI1 | |
| SCHEMBL25444765 | 0.84 | GNAO1 (0.34) | PRMT6CARM1PRMT1PRMT8GNAO1 | |
| SCHEMBL10092707 | 0.84 | DRD2 (0.42) | GNAO1KCNH2GNAI3GNAI1 | |
| SCHEMBL8252286 | 0.82 | CYP1A2 (0.40) | PRMT6CARM1PRMT1PRMT8 | |
| SCHEMBL25075208 | 0.82 | NCF1 (0.39) | PRMT6CARM1PRMT1PRMT8GNAO1 | |
| SCHEMBL25565704 | 0.82 | CARM1 (0.50) | PRMT6CARM1PRMT1PRMT8POLB | |
| SCHEMBL25075447 | 0.82 | NPC1 (0.41) | GNAO1POLBHTTGNAI3GNAI1 | |
| SCHEMBL26445312 | 0.81 | GNAO1 (0.37) | PRMT6CARM1GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | PRMT6 497/4885CARM1 569/4885PRMT1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.